Form 4: Assembly Biosciences Executive Equity Grant Disclosure

Chief Manufacturing Officer Nicole S. White received 14,000 restricted stock units following shareholder approval of the 2018 Stock Incentive Plan amendment.

Summary

• Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, Inc., was granted 14,000 restricted stock units (RSUs).
• The grant was originally approved on March 29, 2026, but remained contingent on shareholder approval of an amendment to the 2018 Stock Incentive Plan.
• Shareholder approval was obtained on June 4, 2026, triggering the issuance of the RSUs.
• The RSUs vest in four equal annual installments starting March 29, 2027, through March 29, 2030.
• The reporting person's total beneficial ownership is now 48,145 shares, adjusted for a prior administrative error of 3,332 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company fundamentals.

Positives

• Alignment of executive compensation with long-term shareholder interests through multi-year vesting schedules.
• Successful shareholder approval of the 2018 Stock Incentive Plan amendment, providing necessary equity capacity for compensation programs.

Negatives

• Disclosure of a prior administrative error resulting in an overstatement of 3,332 shares in previous filings.

Risks

• Vesting is contingent upon the reporting person's continuous service to the company through each vesting date.

Future Outlook

The RSUs are scheduled to vest in four equal annual installments on March 29 of 2027, 2028, 2029, and 2030, provided the reporting person maintains continuous service.

Industry Context

StockSavvy.ai notes that equity-based compensation remains the standard for retaining executive talent in the biotechnology sector, particularly as companies transition through clinical development phases.

Comparison to Industry Standards

• The use of four-year vesting schedules for RSU grants is consistent with standard corporate governance practices for mid-cap and small-cap biotech firms.
• The reliance on shareholder approval for plan amendments is a standard regulatory requirement for maintaining compliance with exchange listing rules.

Corporate Governance

Stakeholder Impact

• Shareholders: Dilution impact is mitigated by the long-term vesting schedule.
• Employees: Reinforces the company's commitment to equity-based incentive structures.

Next Steps

• Vesting of the first tranche of RSUs on March 29, 2027.

Key Dates

Keywords

ASMB, Assembly Biosciences, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, Equity Incentive Plan